register

Marketing & Strategy

The future of the pharmaceutical and GP engagement model 

Health Industry Hub | March 18, 2020 |
[Total: 1    Average: 4/5]

As many GPs are no longer seeing pharma reps there is a growing demand for pharma companies to be forward-thinking and to look to innovative digital communication solutions, reveals a new industry white paper.   

The evolving commercial landscape provides the imperative for a new way of doing business. For pharma companies, this means recognising that GPs are time poor, and whilst choosing not to see drug reps, are raising their digital interactions with pharma. 

Half of GPs are choosing not to see drug reps. This leading to questions over what the future of pharma interactions look like, reveals a new industry white paper.

A series of surveys conducted by independent medical publisher Australian Doctor Group (ADG) shows more than half (54%) say they are too busy to see them, 53% believe they aren’t an objective source of information and 35% prefer to get their information from other places.

The decline in GP engagement is not for lack of trying on pharma’s part – with more than 40% of GP responders reporting that reps attempt to see them or speak to them in person every week.

The surveys’ findings are published for the first time in ADG’s The future of the pharmaceutical and GP engagement model white paper, which warns that the situation is set to worsen with rising GP workloads and a shift to sourcing clinical information online.

Latest Department of Health figures cited in the paper reveal Australian GPs are delivering 18% more services a year than they did a decade ago – leaving them increasingly time poor.

Meanwhile, qualitative research commissioned by ADG shows GPs are looking for real-time information and are routinely using Google searches during patient consults to make sure they have the most up-to-date information to hand.

Australian pharma companies have been slow to respond to this changing environment, the paper reveals

It highlights data from pharmaceutical consulting firm IQVIA that show, despite more GPs choosing not to see reps, investment in marketing materials for drug rep visits increased by 22% between 2015 and 2019.

However, the pharma companies and their marketing teams that are willing to embrace this new digital landscape and engage GPs in the ways they want are seeing strong positive results. 

Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


Human Resources

PAIG co-chairs reflect on industry progress in D&I with sights set on next phase goals

Health Industry Hub | January 17, 2022 |

Human Resources: In this Health Industry Hub podcast, Medicines Australia’s PAIG (Pharma Australia Inclusion Group) co-chairs reflect on their contribution […]

More


News & Trends - Medical Technology

MedTech News -

Stryker announces fellowships for medtech partner projects

Health Industry Hub | January 17, 2022 |

MedTech News: Stryker announced two of its partner research projects have secured fellowship funding from the Australian government’s Researcher Exchange […]

More


News & Trends - Pharmaceuticals

Pharma News - New guidelines recommend Eli Lilly and GSK drugs in treating COVID-19 patients

New guidelines recommend Eli Lilly and GSK drugs in treating COVID-19 patients

Health Industry Hub | January 17, 2022 |

Pharma News: Update to international guidelines recommend two new drugs for the treatment of COVID-19. Eli Lilly’s oral JAK inhibitor, […]

More


News & Trends - Pharmaceuticals

Pharma News -

Novartis shifts focus as CAR T-cell therapy fails to add benefit in non-Hodgkin lymphoma

Health Industry Hub | January 17, 2022 |

Pharma News: Novartis’ chimeric antigen receptor (CAR) T-cell therapy was not found to improve event-free survival over what was seen […]

More